Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effec...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2017-06-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/1044 |
id |
doaj-076afec336cb422cbf6d13cadb52999d |
---|---|
record_format |
Article |
spelling |
doaj-076afec336cb422cbf6d13cadb52999d2020-11-25T02:03:26ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412017-06-0114321222710.20892/j.issn.2095-3941.2017.00542017000054Nanotechnology-based combination therapy for overcoming multidrug-resistant cancerMeng Zhang0Ergang Liu1Yanna Cui2Yongzhuo Huang3Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect <i>in vivo</i>, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from <i>in vitro</i> to <i>in vivo</i> is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.http://www.cancerbiomed.org/index.php/cocr/article/view/1044Drug deliverynanotechnologymultidrug resistancecombination therapycancer therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Meng Zhang Ergang Liu Yanna Cui Yongzhuo Huang |
spellingShingle |
Meng Zhang Ergang Liu Yanna Cui Yongzhuo Huang Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer Cancer Biology & Medicine Drug delivery nanotechnology multidrug resistance combination therapy cancer therapy |
author_facet |
Meng Zhang Ergang Liu Yanna Cui Yongzhuo Huang |
author_sort |
Meng Zhang |
title |
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer |
title_short |
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer |
title_full |
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer |
title_fullStr |
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer |
title_full_unstemmed |
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer |
title_sort |
nanotechnology-based combination therapy for overcoming multidrug-resistant cancer |
publisher |
China Anti-Cancer Association |
series |
Cancer Biology & Medicine |
issn |
2095-3941 2095-3941 |
publishDate |
2017-06-01 |
description |
Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect <i>in vivo</i>, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from <i>in vitro</i> to <i>in vivo</i> is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy. |
topic |
Drug delivery nanotechnology multidrug resistance combination therapy cancer therapy |
url |
http://www.cancerbiomed.org/index.php/cocr/article/view/1044 |
work_keys_str_mv |
AT mengzhang nanotechnologybasedcombinationtherapyforovercomingmultidrugresistantcancer AT ergangliu nanotechnologybasedcombinationtherapyforovercomingmultidrugresistantcancer AT yannacui nanotechnologybasedcombinationtherapyforovercomingmultidrugresistantcancer AT yongzhuohuang nanotechnologybasedcombinationtherapyforovercomingmultidrugresistantcancer |
_version_ |
1724948328277344256 |